A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma

This study is evaluating the safety of a novel stem cell-based gene therapy for patients who have just been diagnosed with glioblastoma (a serious brain tumor) and have already completed standard treatment. The therapy involves genetically engineered stem cells designed to target and kill remaining tumor cells. **You may be eligible if...** - You are between 19 and 70 years old - You have been newly diagnosed with glioblastoma confirmed by imaging - You have already received standard treatment and your expected survival is at least 3 months - You have not received any prior immunotherapy **You may NOT be eligible if...** - Your glioblastoma has returned (recurrent) - You have a pacemaker or other reason that prevents MRI scans - You received Gliadel wafer implants during surgery - You have serious organ dysfunction (liver, kidney, bone marrow, lungs, or heart) - You have another active cancer - You have uncontrolled blood pressure or serious infections - You have autoimmune diseases affecting the central nervous system (e.g., multiple sclerosis) - You have a known allergy to flucytosine or 5-fluorouracil Talk to your doctor to see if this trial is right for you.